Our results revealed that K3-SPG-ISV monotherapy sufficiently induced systemic and long-lasting memory responses and that it acted synergistically with both systemic administration of CPIs and local administration of a CD40 agonist, another innate immune stimulator30, establishing the proof of concept for its clinical application in these intractable cancers, for which tumor puncture is a routine clinical technique. This evidence concerns the gene CD40 and neoplasm.